Cmp Dev Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CMP DEV LLC
CMP DEV LLC has six approved drugs.
There are thirty US patents protecting CMP DEV LLC drugs.
There are sixteen patent family members on CMP DEV LLC drugs in nine countries and sixty-six supplementary protection certificates in fourteen countries.
Drugs and US Patents for Cmp Dev Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | 12,226,528 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cmp Dev Llc | TADLIQ | tadalafil | SUSPENSION;ORAL | 214522-001 | Jun 17, 2022 | RX | Yes | Yes | 11,975,006 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cmp Dev Llc | LIQREV | sildenafil citrate | SUSPENSION;ORAL | 214952-001 | Apr 28, 2023 | DISCN | Yes | No | 11,759,468 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | 12,005,141 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cmp Dev Llc | TADLIQ | tadalafil | SUSPENSION;ORAL | 214522-001 | Jun 17, 2022 | RX | Yes | Yes | 11,382,917 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | 11,723,866 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | 11,458,095 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cmp Dev Llc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3368045 | ⤷ Start Trial |
| European Patent Office | 3731870 | ⤷ Start Trial |
| Canada | 3003028 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2017212409 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2017075463 | ⤷ Start Trial |
| European Patent Office | 3731870 | ⤷ Start Trial |
| China | 111683683 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cmp Dev Llc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2059246 | LUC00371 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF (A) MACITENTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) TADALAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/24/1859 20240930 |
| 0247633 | 97C0118 | France | ⤷ Start Trial | PRODUCT NAME: ATORVASTATINE CALCIQUE TRIHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 21960 DU 19970321; REGISTRATION NO/DATE AT EEC: PL 00018/0240 DU 19961107 |
| 2059246 | 2024C/552 | Belgium | ⤷ Start Trial | PRODUCT NAME: EEN COMBINATIE VAN (A) MACITENTAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN EN (B) TADALAFIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/24/1859 20240930 |
| 2101777 | 300813 | Netherlands | ⤷ Start Trial | PRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125 |
| 1718641 | SPC/GB12/028 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
| 0503785 | C300486 | Netherlands | ⤷ Start Trial | PRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216 |
| 1441735 | 08C0026 | France | ⤷ Start Trial | PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

